Nooshin
Zandi
ab,
Ebrahim
Mostafavi
b,
Mohammad Ali
Shokrgozar
c,
Elnaz
Tamjid
d,
Thomas J.
Webster
b,
Nasim
Annabi
*efg and
Abdolreza
Simchi
*ah
aInstitute for Nanoscience and Nanotechnology, Sharif University of Technology, P.O. Box 11365-11155, Tehran, Iran. E-mail: simchi@sharif.edu; Tel: +98 (21) 6616
bDepartment of Chemical Engineering, Northeastern University, Boston, 02115, USA
cNational Cell Bank Department, Pasteur Institute of Iran, Tehran 13164, Iran
dDepartment of Nanobiotechnology, Faculty of Biological Sciences Tarbiat Modares University, P.O. Box 14115-175, Tehran, Iran
eDepartment of Chemical and Biomolecular Engineering, University of California – Los Angeles, Los Angeles, California 90095, USA. E-mail: nannabi@UCLA.edu; Tel: +1 (310) 267-5927
fCenter for Minimally Invasive Therapeutics (C-MIT), California NanoSystems Institute (CNSI), University of California – Los Angeles, 570 Westwood Plaza, Los Angeles, CA 90095, USA
gHarvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
hDepartment of Materials Science and Engineering, Sharif University of Technology, P.O. Box 11365-11155, Tehran, Iran
First published on 3rd March 2025
Correction for ‘Biomimetic proteoglycan nanoparticles for growth factor immobilization and delivery’ by Nooshin Zandi et al., Biomater. Sci., 2020, 8, 1127–1136, https://doi.org/10.1039/C9BM00668K.
The authors confirm that these corrections do not affect the quantification data, data interpretation, or conclusions of the study.
The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.
This journal is © The Royal Society of Chemistry 2025 |